Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605627 | 0.93 | MET (0.52) | DRD2DRD3METNQO2MGLL | |
| SCHEMBL1848360 | 0.82 | SLC6A2 (0.57) | SIGMAR1SLC6A2SLC6A4SLC6A3TBXAS1 | |
| SCHEMBL2743284 | 0.82 | CARM1 (0.60) | DRD2DRD4CARM1PRMT6 | |
| SCHEMBL1626059 | 0.82 | HRH1 (0.50) | DRD2DRD3METNQO2MGLL | |
| SCHEMBL3605852 | 0.82 | CHRNB4 (0.49) | DRD2DRD3DRD4CHRNB4CHRNA3 | |
| SCHEMBL5251162 | 0.81 | MAOA (0.52) | DRD2DRD3CHRNB4CHRNA3 | |
| SCHEMBL20303982 | 0.80 | KDM1A (0.50) | CHRNB4CHRNA3CARM1PRMT6 | |
| SCHEMBL17166480 | 0.80 | DRD4 (0.60) | DRD4 | |
| SCHEMBL3614551 | 0.78 | CHRNB4 (0.69) | CHRNB4CHRNA3 | |
| SCHEMBL9244259 | 0.78 | CHRNB4 (0.69) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | DRD2 1842/4885DRD3 2558/4885MET 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.